The main purpose of this study is to evaluate CNDO-109 Activated Allogeneic Natural Killer Cells (NK Cells) and how participants with Acute Myeloid Leukemia (AML) respond when given this therapy. The primary objective of this study is to define the maximum tolerated dose (MTD), or the maximum tested dose of CNDO-109-Activated Allogeneic Natural Killer cells infused (given) after preparative chemotherapy. NK cells are a type of blood cell in your immune system that attack cancer cells.
The goal of this Phase II part of this clinical research study is to learn if bevacizumab when given with or without vorinostat can help to control malignant gliomas. The safety of these drug combinations will also be studied. Vorinostat is designed to cause chemical changes in different groups of proteins that are attached to DNA (the genetic material of cells), which may slow the growth of cancer cells or cause the cancer cells to die. Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels.
If the participants are found to be eligible to take part in this study, they will be randomly assigned (as in the flip of a coin) to 1 of 2 groups. If they are in Group 1, they will take bevacizumab.If the participants are in Group 2, they will take vacizumab and vorinostat
The participant may take the study drug(s) for up to 1 year. Participation on this study will end once the participant completes the end-of-dosing visit and long-term follow-up.
The purpose of this research study is to determine if adding a medication that is approved by the United States Food and Drug Administration (FDA) earlier in the normal ovarian stimulation regimen (process that is used by a doctor to help your body release a greater number of mature eggs than it would during a normal cycle) will help you release more eggs or help to lower the dose of hormones that are normally required to help your body release more eggs. This medication is called Human Chorionic Gonadotropin (hCG). hCG is a hormone that supports the normal development of an egg in a woman’s ovaries (the organs in the body that produce a woman’s eggs).
This study is for patients with multiple ipsilateral breast cancers (MIBC). The purpose of this research study is to see if removing only the tissues from the 2 or 3 cancers in the patient's breast (breast conservation surgery) in combination with radiation to the breast, instead of removing the patient's entire breast (mastectomy) is safe in keeping the patient's cancer from coming back in the patient's breast. Patients will be asked to visit the study doctor for follow-up exams for up to 5 years after patients have completed WBI.
Lack of proper sanitation is one of the most significant and widespread health hazards in low and middle- income countries (LMIC). By the end of 2011, 2.5 billion people lacked access to hygienic means of personal sanitation. Further, 1 billion people (15% of the world’s population) lacked access to any facility and engaged in open defecation, a practice carrying enormous health risks. The problem is so widespread and life threatening that the United Nations identified improved sanitation in its millennium development goals for LMIC. One safe and environmentally sensitive solution that addresses the issue of human waste containment is a waste-to- energy system called a biogas system. Waste management biogas systems exist in Ghana but predominantly in large institutions; they have not been implemented in economically disadvantaged, rural communities (Bensah & Brew-Hammond, 2010). In fact, few sanitation systems of any kind exist in rural Ghana where the majority of the nation’s most economically disadvantaged live. The rural village of Okurase in the eastern region of Ghana and its supporting NGO have a longstanding relationship with MUSC. They propose to implement a biogas system that would reduce open defecation, reduce the use of charcoal and wood in cooking, and reduce the use of heavy chemicals in farming. A physicist and engineer have developed a method using a 3-prong approach that can be installed in the village. The Okurase Biogas System will include a private building with toilets. Human waste enters a chamber where it is converted to gas. This gas is harnessed as a dual energy source for cook stoves and organic fertilizer. The Chief and Elders of the village have embraced this technology and support its implementation. More information is needed to learn how to promote uptake of such a system by village residents. Therefore, in line with the overall goals for this village of developing a sustainable infrastructure to improve water, sanitation, health, economic self-sufficiency and food security in Okurase, the specific aims of this application are to: 1) determine the feasibility and acceptability of the biogas system; 2) assess the attitudes and knowledge of biogas technology over time; and, 3) determine factors that promote or preclude system sustainability.
Lesbian and bisexual women under utilize cervical cancer screening programs as compared to heterosexual women. This study uses interviews to explore, identify, and examine the factors that influence cervical cancer screening participation among lesbian and bisexual women. The findings from this study will generate new knowledge and enhance understanding of the cervical cancer screening among lesbian and bisexual women. The findings from this study can be used to design specific interventions to improve cervical cancer screening among lesbian and bisexual women.
The purpose of this study is to find out more about talimogene laherparepvec (formerly known as OncoVEXGM-CSF), in people with advanced melanoma when given in combination with another drug called ipilimumab.
Talimogene laherparepvec is a modified herpes simplex type-1 virus (the ‘cold sore’ virus) that has a medicine called human granulocyte macrophage colony-stimulating factor (GM-CSF) added to it. Human GM-CSF is a medicine used to treat patients with white blood cell counts that are low. Talimogene laherparepvec is still experimental and is not approved by the FDA.
This study is for adult males and females who have been diagnosed with cancer. This study involves a new investigational drug called PF-05212384 that is currently not FDA-approved for sale in this country. The first goal of this study is to determine the highest dose of PF-05212384 that can be tolerated without endangering the patients (MTD). When the MTD is found, additional patients will be enrolled to the study to examine the safety and tolerability of PF-05212384 in combination with other study drugs. Each participant will receive only one of the two possible combinations described below of study drugs while in this study. Patients may be in this study for approximately up to 1 year. Depending on the treatment he/she is given, he/she may need to visit the clinic daily, after the initial dose period. The visits to the clinic may then be as much as every 4-6 days during the first 6 “cycles” (each cycle is approximately 28 days) of treatment.
This clinical trial uses an investigational drug called SGN-CD70A in patients that have Non-Hodgkin lymphoma (NHL) or renal cell carcinoma (RCC). This study is being done to find out what side effects (unwanted effects) are caused in subjects with NHL or RCC who are given SGN-CD70A. This study will also look at other effects of SGN-CD70A, including its effect on the subject's cancer.
Subjects will be enrolled to receive low doses of SGN-CD70A in the beginning. If the subjects given low doses do not have bad side effects, the next subjects will be given a higher dose of SGN-CD70A. After this, subjects just starting SGN-CD70A will be given higher or lower doses, depending on the side effects subjects have already had. This will continue until the highest dose of SGN-CD70A that does not cause bad side effects is found.
Approximately 95 people will take part in this research study.